Quote Ohm: Just 3 of the 89 indications would p
Post# of 148187
(Total Views: 534)
Posted On: 07/10/2022 8:12:44 PM
Quote Ohm:
Just 3 of the 89 indications would put us past three figures, NASH, longhaulers and cancer.
How can we not love this possibility? Triple digit would be wonderful. I would add the we need our very first approval of HIV Combo hopefully by spring to mid summer of 2023. Have to have our safety aggregate included with our first approval in HIV. Then by the end of 2023 approvals for Cancer and Long haulers. Nash will take longer to do a phase 3 trial with the average Nash trial I believe is a year. Maybe by mid 2024?
Then as we get our first few approvals under our belt and generate revenue to start other trials as fast as possible on the other indications as we build our platform drug into a mirror image of Humira’s growth as it acquired its 12+ approvals. Just like Dr. Kelly stated… we believe we should model our platform after Humira.
Makes sense to me to model our approvals after a proven company that has the highest ever revenue of all drugs in Humira. It’s like the old saying goes… why re-invent the wheel…the model is out there already. No need to do anything different.
Read More: https://investorshangout.com/post/view?id=643...z7YgXzwUkX
Just 3 of the 89 indications would put us past three figures, NASH, longhaulers and cancer.
How can we not love this possibility? Triple digit would be wonderful. I would add the we need our very first approval of HIV Combo hopefully by spring to mid summer of 2023. Have to have our safety aggregate included with our first approval in HIV. Then by the end of 2023 approvals for Cancer and Long haulers. Nash will take longer to do a phase 3 trial with the average Nash trial I believe is a year. Maybe by mid 2024?
Then as we get our first few approvals under our belt and generate revenue to start other trials as fast as possible on the other indications as we build our platform drug into a mirror image of Humira’s growth as it acquired its 12+ approvals. Just like Dr. Kelly stated… we believe we should model our platform after Humira.
Makes sense to me to model our approvals after a proven company that has the highest ever revenue of all drugs in Humira. It’s like the old saying goes… why re-invent the wheel…the model is out there already. No need to do anything different.
Read More: https://investorshangout.com/post/view?id=643...z7YgXzwUkX
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼